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Abstract
Objective To assess the clinical outcomes of surgical
treatment for acquired vulvar lymphangioma circumscrip-
tum in patients who received radical surgery and/or adju-
vant radiation therapy for cervical cancer.
Methods A retrospective chart review of eight patients was
performed to assess the demographic information, chief
complaints, treatment modality for cervical cancer, location,
and primary treatment modality for vulvar LC, postoperative
changes in symptoms, and/or signs, the development of local
recurrence and the outcome of patients.
Results All eight patients were previously diagnosed with
cervical cancer FIGO clinical stage IA to IIA and received
surgery, radiation therapy, or concurrent chemoradiation
therapy. Microscopic examination revealed multiple, dila-
ted, D2-40-positive dermal vascular channels containing
eosinophilic proteinaceous material, consistent with LC.
Most chief complaints showed considerable improvements
on assessment at the outpatient clinic after the primary
surgery. No patient showed aggravation of symptoms. Two
patients developed local recurrences. One patient devel-
oped recurrence on the opposite side 13 months after local
excision. We performed a second wide local excision.
Another patient developed recurrence 47 months after the
primary surgery. Since the lesion was very small and
localized, we decided to manage it conservatively, but
monitor it very closely. The remaining six patients
remained free of recurrence.
Conclusion It is not easy for gynecologists to have an
initial clinical diagnosis of LC, because there are a number
of diseases that exhibit similar clinical manifestation to that
of vulvar LC. Even if it is diagnosed correctly, local
recurrence often occurs. Relevant symptoms associated
with LC are not only distressing, but also affect patients’
quality of life. Based on our data, we propose that surgical
treatment could provide a more long-lasting answer com-
pared to other treatment modalities, since it is beneficial in
terms of clinical outcomes. In the future, a long-term fol-
low-up investigation is required to assess the prognosis and
to compare the efficacy and side effects of each modality.
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Introduction
Lymphangioma circumscriptum (LC) is a benign disease of
nonspecific origin. It occurs in the lymphatic vascular
system in the deep dermal and subcutaneous layer. It was
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initially reported by Fox and Fox in 1878 [1], and the term
LC was first used by Malcolm and Morris in 1889 [2]. The
pathogenesis of LC is unclear. Usually, it often occurs in
the proximal part of limbs, which is rich in lymphatic
vasculature such as shoulders, axilla, groin, buttock, and so
on. Even though primary vulvar LC can occur congenitally
(or primarily) due to the developmental defect of the vulvar
lymphatic system, it is a very rare condition [3]. It can also
be acquired (or secondarily) in case of cervical cancer
patients who received radical hysterectomy, pelvic lym-
phadenectomy, or pelvic radiation that can damage the
lymphatics [4]. The linkage between the presentation of LC
as superficial verrucous vesicles and deep lymphatic vas-
culature was suggested [5].
The symptoms of LC are vulvar swelling, pain, pruritus,
eczematous change, and infection. It is cosmetically
problematic and deeply distressing. Therefore, it often
affects patients’ quality of life. When it gets severe, LC can
also affect social and sexual life and produce psychological
problems as well [6]. Therefore, the aim of treatment
includes palliation for symptomatic relief.
Since vulvar LC typically presents as multiple, grossly
verrucous vesicles of various sizes, it may be impossible to
distinguish vulvar LC clinically from herpes zoster,
condyloma acuminatum, genital warts, molluscum conta-
giosum, or lupus verrucosus. In this sense, biopsy is
essential to confirm the diagnosis of LC.
Although diverse treatment modalities of LC have been
attempted, recurrence is a constant problem for gynecolo-
gists. The purpose of this study was to demonstrate and
assess the clinical outcome of surgical treatment for
acquired vulvar LC.
Methods
We found 12 patients who were diagnosed with vulvar LC
at the Department of Obstetrics and Gynecology, Samsung
Medical Center (Seoul, Republic of Korea) from January
2005 to December 2014. In all 12 patients, the diagnosis of
vulvar LC was confirmed histopathologically. Eight of
these patients received surgical excision. Among four
patients who received nonsurgical treatments, one did not
want to receive surgical treatment. She received CO2 laser
treatment four times at the Department of Dermatology,
Samsung Medical Center (Seoul, Republic of Korea) from
July 2012 to December 2012. The remaining three patients
had focal and unilateral lesions. Therefore, we only per-
formed vulvar excisional biopsy for them. They are in the
process of uneventful clinical follow-up. These patients
who did not receive primary surgical treatment were
excluded from this study. To assess the clinical outcome
after the primary surgery of vulvar LC, we reviewed the
medical chart of the outpatient clinic and confirmed the
collected information using a person-to-person phone sur-
vey for each patient. A retrospective chart review was
performed to assess the demographic information, chief
complaints, treatment modality for cervical cancer, loca-
tion of vulvar LC, primary treatment modality for vulvar
LC, postoperative changes in symptoms and/or signs, the
development of local recurrence, and the outcome of
patients. Based on the numeric rating scale (NRS), we
designated the symptoms and/or signs as ‘‘improved’’ when
there were more than four changes in scale before and after
the surgery. We also assessed the remaining clinical
parameters using the NRS method. When it was outside of
this four scale boundary, we designated it as ‘‘stationary’’.
Results
The clinical profiles and surgical outcomes are summarized
in Table 1. The clinical stages of the eight patients were
FIGO stage IIA in four, IB in three and IA in one patient.
All patients received radical abdominal hysterectomy with
bilateral pelvic lymph node dissection. Four of them also
received radiation therapy and two received concurrent
chemoradiation therapy. Therefore, all of them developed
acquired (or secondary) type of vulvar LC. The median age
of patients and age at presentation were 61.5 and 54 years,
respectively. The mean interval between the surgery for
cervical cancer and the development of vulvar LC was
17 years (range 7–31 years). To determine the clinical
outcome of surgical treatment, we chose the symptoms
and/or signs that the patients felt most uncomfortable or
distressing. Chief complaints included pain, edema, pruri-
tus, discharge, and secondary infection, according to the
frequency. Except for patient 3, who received local exci-
sion for unilateral, localized vulvar LC, all had bilateral
lesions. Wide local excision was performed in seven
patients.
Intraoperative gross photographs (Fig. 1a, b), a postop-
erative photograph (Fig. 1c) and histopathologic findings
of patient 8 are shown. Gross examination revealed
hyperpigmented, rugose and studded epidermis with mul-
tiple conglomerated papules measuring up to 0.1–0.5 cm.
The cut sections showed nodularity and papillary projec-
tions with thin-walled cystic cavities in the superficial
dermis. Microscopic examination revealed multiple dilated
dermal vascular channels containing eosinophilic pro-
teinaceous material (Fig. 1d). The lymphatic channels were
lined by a single layer of bland endothelial cells and
highlighted by D2-40 immunostaining (Fig. 1e). There was
a mild inflammatory infiltrate in the upper dermis. The
overlying epidermis was partly hyperkeratotic. There was
no evidence of malignancy.
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Most chief complaints showed considerable improve-
ments on assessment at the outpatient clinic after the pri-
mary surgery. No patient showed an aggravation of the
symptoms. Two patients developed local recurrences:
patient 1 developed recurrence 47 months after the primary
surgery. Since the lesion was very small and localized, we
decided to manage it conservatively, but monitor it very
closely. Patient 3 developed recurrence on the opposite side
13 months after local excision. We performed a second
wide local excision. The remaining six patients remained
free of recurrence.
Discussion
We performed a thorough search for previous literature on
the treatment of vulvar LC using the US National Library
of Medicine’s PubMed database and the Royal College of
Obstetricians and Gynecologists database using the term
‘‘lymphangioma circumscriptum’’ and the word ‘‘vulva’’.
Among 44 reported cases (in any language) of vulvar LC
by December 2014, only 24 cases acquired LC. Out of the
24 previous cases of LC, 21 cases were associated with
treatment of cervical cancer (87.5 %). In the remaining
three cases, patients had Crohn’s disease, recurrent cel-
lulitis, and leg edema. To the best of our knowledge, this
report exhibits the largest number of case series from a
single institution so far.
The etiology of acquired LC remains to be clarified. The
suggested etiology is the architectural disruption of previ-
ously normal lymphatic channels, leading to LC by the
sequestration and further dilation of previously normal
lymphatics [7, 8]. Causative factors of vulvar-acquired LC
are radical hysterectomy, pelvic lymphadenectomy, and/or
radiation therapy for cervical cancer, infectious disease
(filariasis, genital tuberculosis, erysipelas, sexually
Fig. 1 Intraoperative and postoperative photographs (a–c) and
microscopic findings (d, e) of vulvar LC (patient 8). a Gross finding.
b Right after the surgical excision. c Postoperative finding.
d Histopathologic examination revealed hyperkeratotic, hyperplastic
squamous epithelium in the epidermis and multiple, variable-
sized spaces lined by flat endothelial cells in the superficial dermis.
The dilated dermal lymphatic channels contain fibrinous material and
few inflammatory cells. e Immunohistochemically, the lymphatic
endothelial cells were positive for D2-40 [1]
160 Arch Gynecol Obstet (2016) 293:157–162
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transmitted disease, and lymphogranuloma venereum),
Crohn disease, primary dysplastic angiopathy, bilateral
varicose veins in the lower extremities, dermopathy due to
penicillamine or corticosteroids, surgical trauma, keloids,
scleroderma, and rhabdomyosarcoma [9]. If the patient has
no causative factor, the diagnosis of primary vulvar LC is
made. However, this is an extremely rare condition [10].
According to our experiences, the radicality of surgical
treatment seems to have more impact on the development
of vulvar LC than the tumor stage. Indeed, there may be a
tendency that the surgical radicality increases as the tumor
stage gets high. Nevertheless, considering the mechanism
by which surgical procedure damages the lymphatic vas-
cular channels, we think that vulvar LC occurs more fre-
quently in patients who received radical surgery than in
those who did not receive radical surgery. Regarding the
type of therapy chosen for cervical cancer, our patients
received different options of treatment from each other,
including surgery only, surgery, adjuvant chemotherapy,
and/or radiation therapy, since the patients were treated by
different clinicians and each of them had different treat-
ment policies. Even though some subgroups of patients
exhibited the same clinical stage (IIA in 4 patients and IB
in 3), correlating the type of therapy with the presence of
vulvar LC seems to be inadequate in this study.
Differential diagnoses of vulvar LC include molluscum
contagiosum, herpes zoster, genital warts, lupus verruco-
sus, leiomyoma, cellular angiofibroma, angiomyofibrob-
lastoma, and aggressive angiomyxoma [11, 12]. As
described above, the clinical manifestation of various
infectious disease and tumorous conditions are similar to
that of vulvar LC. Therefore, the histopathologic confir-
mation of diagnosis through biopsy is crucial to avoid
misdiagnosis and mistreatment. In addition, the correct
diagnosis is essential to determine the optimal therapeutic
strategy, which may satisfy both patients and clinicians.
There is no consensus about the standard treatment for
vulvar LC. Treatment modalities reported in the literature
include surgical excision, abrasive methods (CO2 laser,
liquid nitrogen, electrocoagulation or sclerosing therapy),
and observation. There are several therapeutic options for
surgical excision, such as labiaectomy, vulvectomy (sim-
ple, partial, or radical), mass excision, and wide local
excision. In general, it is conducted to reduce labium
majora and minora, as well as to excise vulvar verrucous
and edematous lesions as much as possible. A previous
study reported that with a single surgery for vulvar LC, at
least 10 years of disease-free, long-term cure is possible
[13]. Several authors have proposed that the most preferred
treatment of choice for both primary and acquired LC is
surgical excision [10]. The age of presentation is relatively
low, and considerable cosmetic problems affect patients
physically and psychologically. In this study, six of eight
patients developed no recurrence. One of two patients who
developed local recurrence received second complete sur-
gical excision. Consistent with previous data, we also
propose that surgical excision is a treatment of choice for
vulvar acquired LC. Indeed, it is not proven to be superior
compared to other treatment modalities [8]. Ghaem-
maghami et al. [12] reported the recurrence rate after sur-
gery was 23.1 % during follow-up periods, ranging from 6
to 81 months. Vlastos et al. [14] stated that the postoper-
ative recurrence rate might be twice as high in LC without
surgical treatment. To prevent developing recurrence,
excision of the lesion should be through the full thickness
of the skin and subcutaneous tissue down to the deep fascia
[11]. By doing this, the deep-feeding lymphatic cisterns of
subcutaneous layer, which are considered to be the main
cause of the recurrence, can be excised. We assume that the
extent of the primary lesion has significant impact on
recurrence and surgical outcome. Treatments should be
individualized according to the extent, type, and severity of
disease and patient’s preference.
Non-surgical treatment including cryotherapy, scle-
rotherapy, and laser therapy have been attempted to pre-
vent surgery-related complications. Actually, in clinical
practice, CO2 laser, electrocoagulation, or sclerosing ther-
apy has been performed for local therapy. Though in some
cases, those treatment options have been reported to be
effective in controlling the symptoms, a thorough literature
search revealed negative results. There were no available
data regarding the effectiveness of local therapy for vulvar
LC using a large-scale patient cohort. As a result, currently,
no local therapy has been proved to reliably improve
symptoms such as pain and/or pruritus. Cryotherapy seems
to be rather ineffective, with low remission and high
recurrence rates. A previous study showed that scle-
rotherapy is very effective in a short term [15], but scle-
rotherapy agents have a potential risk of severe systemic,
local, and cosmetic side effects. In contrast, regarding CO2
laser therapy, the effectiveness of pulsed dye lasers was
reported in 2005 [16]. Favorable outcomes using a 900-nm
diode laser and CO2 laser were also reported in 2006 [17].
Similarly, successful treatment of congenital vulvar LC
with CO2 and long-pulsed Nd:YAG lasers has been
recently reported [18]. More clinical data on laser therapy
are necessary. We believe that it will be favorable to
consider surgical treatments when fulfilling the following
criteria: (1) the large size of mass and deep lesions of
vulvar LC; (2) distressing symptoms such as pain, pruritus,
edema, discharge, and secondary infection; (3) treatment
failure after non-surgical treatment.
A limitation of this study was the relatively small
sample size and the lack of a comparison group, i.e.,
patients who did not receive non-surgical treatment. It
would be interesting to observe patients who received
Arch Gynecol Obstet (2016) 293:157–162 161
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medical treatment and compare the results. We considered
that this study is just a preliminary one to analyze the
clinical outcomes of surgical treatment for vulvar LC. We
are now collecting the data on non-surgical treatment for
vulvar LC. We are planning to report the experience of
non-surgical treatment for vulvar LC and compare the
results between patients who received radical surgery and
those who did not.
In conclusion, we assessed the clinical outcomes of
primary surgical treatment for patients with vulvar LC.
Because there are a number of diseases that exhibit similar
clinical manifestation to that of vulvar LC, it is not easy for
gynecologists to have an initial clinical diagnosis. Even if it
is diagnosed correctly, relapse often occurs. Relevant
symptoms are not only distressing, but also affects patients’
quality of life. The treatment modalities may differ
depending on patients’ age, the extent of the lesion, and the
preference of each patient and clinician. Nevertheless, we
propose that surgical treatment could provide a more long-
lasting answer compared to other treatment modalities,
since it is beneficial in terms of clinical outcomes. In the
future, a long-term follow-up investigation is required to
assess the prognosis and to compare the efficacy and side
effects of each modality.
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